ZTS vs TEVA
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ZTS · Zoetis$79.40 ▼ 3.30%
TEVA · Teva Pharmaceutical Industries$42.61 ▲ 1.99%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ZTS -32.7%
- TEVA +75.6%
Head to head
| Metric | ZTS | TEVA |
|---|---|---|
| Price | $79.40 | $42.61 |
| Change today | ▼ 3.30% | ▲ 1.99% |
| Market cap | $32.26B | $49.72B |
| Return, 3 months | +6.1% | +17.9% |
| Return, year to date | -35.9% | +36.5% |
| Return, 1 year | -32.9% | +77.8% |
| P/E (TTM) | 13.4 | 99.1 |
| P/B | 9.8 | 6.2 |
| P/E percentile vs own 5y | 10th | 100th |
| Dividend yield | 2.63% | – |
| Revenue growth (YoY, latest qtr) | -0.2% | -0.8% |
| Net profit growth (YoY) | -4.8% | -303.2% |
| Gross margin | 71.7% | 52.5% |
| Operating margin | 37.9% | 18.7% |
| Net margin | 27.7% | 4.1% |
| Return on equity | 64.9% | 9.7% |
| Analyst target vs. price | +13.4% | +16.9% |
| Analyst buy share | 36% | 100% |
| RSI (14) | 51 | 63 |
| 30-day volatility | 43.9% | 26.7% |
| Max drawdown, 1 year | -52.3% | -21.8% |
| Trend read | Leaning bearish | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- TEVA is the largest of the group by market value.
- TEVA has returned the most over the past year.
- ZTS carries the lowest trailing P/E.
- ZTS is growing revenue fastest.
- ZTS keeps the most profit per dollar of sales.
- TEVA has been the calmest stock over the last 30 days.